University Retina and Macular Associates

Publications

Veeral S. Sheth, MD, MBA, FASRS, FACS, University Retina & Macular Associates

• Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, Abbey AM, Almedia DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Mein L, Sheth VS, Wolfe JD, Singer MA, Danzig CJ. The real-world efficacy and safety of faricimab in neovascular age-relatd macular degeneration: the TRUCKEE study- 6 month results. Eye 2023.
• Patel PN, Patel PA, Land MR, Bakerkhatib-Taha I, Ahmed H, Sheth V. Targeting the complement cascade for treatment of dry age-related macular degeneration. Biomedicines 2022,10,1884.
• Sheth V, D’Rozario M, Gune S, Blotner S. Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophth 2022;7e000957.
• Poor SH, Weissgerber G, Adams CM, Bhatt H, Browning DJ, Chastain J, Ciulla TA, Ferriere M, Gedif K, Glazer LC, Joondeph BC, Normand G, Sheth V, Watters C, Grosskreutz CL. A randomized, double-masked, multicenter trial of topical acrizanib (LHA510), a tyrosine kinase VEGF-receptor inhibitor, in treatment-experienced subjects with neovascular age-related macular degeneration. AJO 2022, in press.
• Singer M, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology, 2022 in press.
• Graff J, Sheth V, Chang RT, Menezes A, Barteselli G, Malhotra V. Conjunctiva and Tenon’s capsule handling in the Port Delivery System with ranibizumab implant insertion procedure: surgical pearls. Ophthalmic Surg Lasers Imaging Retina, 2022 53(5):266-273.
• Patel P, Sheth V. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD). J. Clin. Med. 2021, 10(11): 2436.
• Sokol JT, Schechet SA, Komati R, Eliott D, Vavvas DG, Kaplan RI, Ittiara ST, Farooq AV, Sheth VS, MacCumber MW, Ke R, Gentile RC, Skondra D. Macular hole closure with medical treatment. Ophthalmology Retina. 2021 Apr;5(4):348-356.
• Tsipursky M, Byun M, Jager R, Sheth V. Anatomical and functional outcomes of relaxing parafoveal nasal retinotomy for refractory macular hole repair. Journal of Vitreoretinal Diseases. 2021 accepted.
• Yu HJ, Kiernan DF, Eichenbaum D, Sheth V, Wykoff C. Home monitoring of age-related macular degeneration: utility of the ForeseeHome device for detection of neovascularization. Ophthalmology Retina. 2021 Apr;5(4)348-356.
• Bhagat D, Kirby B, Bhatt H, Jager R, George M, Sheth V. Patient preferences associated with anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration and diabetic macular edema. Clinical Ophthalmology. 2020 Oct: 14: 2975-2982.
• Sheth V, Hariprasad SM, Dhoot D. Private equity’s game plan and why it should matter to us. Ophthalmic Surg Lasers Imaging Retina. 2020 Aug;51(8):424-427.
• Oh DJ, Sheth V, Fishman GA, Grassi MA. Simplex crumbs homologue 1 maculopathy masquerading as juvenile X-linked retinoschisis in male patients. J Vitreoretin Dis. 2020 Oct;4(5):437-440.
• Horton MB, Brady CJ, Cavallerano J, Abramoff M, Barker G, Chiang MF, Crockett CH, Garg S, Karth P, Liu Y, Newman CD, Rathi S, Sheth V, Silva P, Stebbins K, Zimmer-Galler I. Practice Guidelines for Ocular Telehealth-Diabetic Retinopathy, Third Edition. Telemedicine and e-Health, 2020 Apr; 26(4):1-50.
• Eichenbaum DA, Buznego C, Weng CY, Dhoot DS, Wykoff CC, Sheth VS. When and how to incorporate steroids for persistent macular edema: A discussion of real-world treatment optimization strategies. Ophthalmic Surg Lasers Imaging Retina. 2018 Jul 1;49(7):S5-S15.
• Dunn EN, Hariprasad SM, Sheth VS. An overview of the Fovista and rinucumab trials and the fate of anti-PDGF medications. Ophthalmic Surg Lasers Imaging Retina. 2017 Feb 1;48(2):100-104.
• Sahni S, Watson RM, Sheth VS. Actinomyces neuii endophthalmitis after intravitreal anti-VEGF injection. Retina Cases and Brief Reports. 2017 Summer;11(3):281-282.
• Metelitsina TI, Sheth VS, Patel SB, Grassi MA. Peripheral retinopathy associated with aplastic anemia. Retina Cases and Brief Reports. 2017 Spring;11(2):108-110.
• Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, Hariprasad SM. Cystoid macular edema assoiciated with fingolimod use for multiple sclerosis. Arch Ophthalmol. 2013 Jan; 131(1):103-7.
• Afshar AR, Hariprasad SM, Jampol LM, Sheth VS. Use of intravitreous bevacizumab to treat macular edema in west nile virus chroioretinitis. Arch Ophthalmol. 2012 Mar; 130(3):396-8.
• Kiernan DF, Lin TK, Sheth V, Jager RD. Pharmacotherapy of retinal diseases with ranibizumab. Clinical Medicine: Therapeutics. 2009 Apr:175-182.
• Sheth V, Shapiro M. Detection of facial hypotonia and diagnosis of FSHD. Arch Ophthalmol. 2008 May; 126:745-6.
• Shukla D, Scanlan P, Tiwari V, Sheth V, Clement C, Guzman-Hartman G, Dermody TS, Valyi-Nagy T. Expression of nectin-1 in the normal and HSV-1-infected murine brain. Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):341-7.
• Valyi-Nagy T, Sheth V, Clement C, Tiwari V, Scanlan P, Kavouras JH, Guzman-Hartman G, Dermody TS, Shukla D. Herpes simplex virus entry receptor nectin-1 is widely expressed in the murine eye. Current Eye Research. 2004 Oct-Nov;29(4-5):303-309.

Harit K. Bhatt, M.D., M.B.A, F.A.C.S., FASRS, University Retina & Macular Associates

Sheth V, Marcet M, Chiranand P, Bhatt HK, Lamkin JC, Jager RD. The Massachusetts Eye and Ear Infirmary Review Manual for Ophthalmology, Fourth Edition. Baltimore: Lippincott, Williams & Wilkins, 2011.

Maria Lozano-Vazquez, M.D., Jose Garcia-Gonzalez, M.D., Veeral Sheth, M.D., F.A.C.S., Harit Bhatt, M.D., F.A.C.S., Sundeep Grandhe, M.D., Madhu Amara, M.D., Rama D. Jager, M.D., M.B.A., F.A.C.S. Complications of Intravitreal Injections. IN V. Alfaro, E. Jablon, J. Kerrison, K. Sharpe, and M. Rodriguez- Fontal: Age-Related Macular Degeneration. Wolters Kluwer/ Lippincott Williams & Wilkins

Bhatt HK. Outpatient Surgical Specialities. IN Sheth V: Shelf-life Pediatrics. Wolters Kluwer/ Lippincott Williams & Wilkins

Meena S. George, M.D., Ph.D., FASRS, University Retina & Macular Associates

 Bhagat D, Kirby B, Bhatt H, Jager R, George M, Sheth V. Patient preferences associated with anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration and diabetic macular edema. Clinical Ophthalmology. 2020 Oct: 14: 2975-2982. 

Rama D. Jager, M.D., M.B.A., F.A.C.S., University Retina & Macular Associates

Wang AL, Rao VR, Chen JJ, Lussier YA, Rehman J, Huang Y, Jager RD, Grassi MA. Role of FAM18B in diabetic retinopathy.
Mol Vis. 2014 Aug 4;20:1146-59.

Chedid EH, Golden QR, Jager RD. Operational challenges in delivery of a charity care program for diabetic retinopathy screening in an urban setting.
Perm J. 2013 Winter;17(1):21-5. doi: 10.7812/TPP/12-041.

Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.

Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration.
Retina. 2010 Nov-Dec;30(10):1573-8.

Gabrielian A., Hariprasad S., Jager R., Green J., Mieler W. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life.
Eye (Lond). 2010 Jan;24(1):29-35. Epub 2009 Mar 27.

Jager R., Mieler W., Miller J. Age-related Macular Degeneration.
New England Journal of Medicine. 2008 Jun 12;358(24):2606-17.

Benevento J., Jager R., Noble A., Latkany P., Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R; Toxoplasmosis Study Group. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.
Arch Ophthalmol. 2008 Aug;126(8):1152-6.

Mazzulla D., Hariprasad S., Jager R., Mieler W. Short-Term intraocular pressure trends after intravitreal injection of bevacizumab (Avastin). Retinal Cases & Brief Reports.
(Accepted 13 December 2007, and Article in Press)

Mojica, G., Hariprasad, S., Jager R., Mieler, W. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.
British Journal of Ophthalmology. 2008 Apr;92(4):584.

Hariprasad S., Mieler W., Grassi M., Green J., Jager R., Miller L. Vision-related quality of life in patients with diabetic macular oedema.
British Journal of Ophthalmology. 2008 Jan;92(1):89-92. Epub 2007 Jun 21.

Shukla D., Aiello L., Kolluru C., Baddela S., Jager R., Kim R. Relation of optical coherence tomography and unusual angiographic leakage patterns in central serous chorioretinopathy.
Eye. 2007 Apr 20.

Shukla D., Dhoble P., Jager R., Aiello L.P., Ramasamy K. Closure of macular hole following vitrectomy for diabetic tractional macular detachment.
Eye. 2006 Dec;20(12):1386-8.

Singh, R., Jager, R., Alfaro, V., Puliafito, C. The Use of Optical Coherence Tomography in the Diagnosis and Assessment of AMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.

Wirostko, W., Jager, R., Singh, R., Kiernan, D., Mieler, W. Intraocular Foreign Bodies.
In Modern Management of Ocular Trauma, 2006.

Alfaro, D., Loethen, M., Jager, R., Kim, R. Ranibizumab (Lucentis™) for ARMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.

Agurto-Rivera R., Diaz-Rubio J., Torres-Bernal L., Macky T., Colina-Luquez J., Papa-Oliva G., Jager R,, Martinez-Jardon S., Fromow-Guerra J., Quiroz-Mercado H. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study.
BMC Ophthalmology. 2005 Nov 25;5:27.

Jager, R., Timothy, N., Coney, J., Katalinic, P., Cavicchi, R., Cavallerano, J., Aiello, L. Congenital Retinal Macrovessel.
Retina. 2005 Jun;25(4):538-540.

Jager R., Aiello, L., Patel S., Cunningham, E. Risks of Intravitreous Injection: A Comprehensive Review.
Retina. 2004 Oct;24(5):676-98.

Shahinian, L., Jain, S., Jager, R., et al. Dilute Topical Proparacaine for Pain Relief after Photorefractive Keratectomy.
Ophthalmology 1997; 104: 1327-1332.

Heymann, J., Jager, R., Subramaniam, S. Expression of Bacteriorhodopsin in Sf9 and COS-1 Cells.
Journal of Biomembranes and Bioenergetics 1997; 29: 55-59.

Jager, R., Chen, F. Musculoskeletal Photodiagnosis: Hereditary Multiple Exostoses.
Journal of Musculoskeletal Medicine 1998; 15(6): 63-64.

Chapters

Veeral S. Sheth, MD, MBA, FASRS, FACS, University Retina & Macular Associates

• Sheth V, Zaslau S, Casanova R, eds. Lippincott Q&A Medicine: Review for Clinical Rotations and Exams. Baltimore: Lippincott, Williams & Wilkins, 2015.
• Sheth V, Zaslau S, Casanova R, eds. Shelf-Life Surgery. Baltimore: Lippincott, Williams & Wilkins, 2014.
• Sheth V, Zaslau S, Casanova R, eds. Shelf-Life Obstetrics and Gynecology. Baltimore: Lippincott, Williams & Wilkins, 2014.
• Sheth V, Zaslau S, Casanova R, eds. Shelf-Life Pediatrics. Baltimore: Lippincott, Williams & Wilkins, 2014.
• Sheth V, Marcet M, Chiranand P, Bhatt HK, Lamkin JC, Jager RD. The Massachusetts Eye and Ear Infirmary Review Manual for Ophthalmology, Fourth Edition. Baltimore: Lippincott, Williams & Wilkins, 2011.

Rama D. Jager, M.D., M.B.A., F.A.C.S., University Retina & Macular Associates

Wang AL, Rao VR, Chen JJ, Lussier YA, Rehman J, Huang Y, Jager RD, Grassi MA. Role of FAM18B in diabetic retinopathy.
Mol Vis. 2014 Aug 4;20:1146-59.

Chedid EH, Golden QR, Jager RD. Operational challenges in delivery of a charity care program for diabetic retinopathy screening in an urban setting.
Perm J. 2013 Winter;17(1):21-5. doi: 10.7812/TPP/12-041.

Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.

Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.

Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration.
Retina. 2010 Nov-Dec;30(10):1573-8.

Gabrielian A., Hariprasad S., Jager R., Green J., Mieler W. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life.
Eye (Lond). 2010 Jan;24(1):29-35. Epub 2009 Mar 27.

Jager R., Mieler W., Miller J. Age-related Macular Degeneration.
New England Journal of Medicine. 2008 Jun 12;358(24):2606-17.

Benevento J., Jager R., Noble A., Latkany P., Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R; Toxoplasmosis Study Group. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.
Arch Ophthalmol. 2008 Aug;126(8):1152-6.

Mazzulla D., Hariprasad S., Jager R., Mieler W. Short-Term intraocular pressure trends after intravitreal injection of bevacizumab (Avastin). Retinal Cases & Brief Reports.
(Accepted 13 December 2007, and Article in Press)

Mojica, G., Hariprasad, S., Jager R., Mieler, W. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.
British Journal of Ophthalmology. 2008 Apr;92(4):584.

Hariprasad S., Mieler W., Grassi M., Green J., Jager R., Miller L. Vision-related quality of life in patients with diabetic macular oedema.
British Journal of Ophthalmology. 2008 Jan;92(1):89-92. Epub 2007 Jun 21.

Shukla D., Aiello L., Kolluru C., Baddela S., Jager R., Kim R. Relation of optical coherence tomography and unusual angiographic leakage patterns in central serous chorioretinopathy.
Eye. 2007 Apr 20.

Shukla D., Dhoble P., Jager R., Aiello L.P., Ramasamy K. Closure of macular hole following vitrectomy for diabetic tractional macular detachment.
Eye. 2006 Dec;20(12):1386-8.

Singh, R., Jager, R., Alfaro, V., Puliafito, C. The Use of Optical Coherence Tomography in the Diagnosis and Assessment of AMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.

Wirostko, W., Jager, R., Singh, R., Kiernan, D., Mieler, W. Intraocular Foreign Bodies.
In Modern Management of Ocular Trauma, 2006.

Alfaro, D., Loethen, M., Jager, R., Kim, R. Ranibizumab (Lucentis™) for ARMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.

Agurto-Rivera R., Diaz-Rubio J., Torres-Bernal L., Macky T., Colina-Luquez J., Papa-Oliva G., Jager R,, Martinez-Jardon S., Fromow-Guerra J., Quiroz-Mercado H. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study.
BMC Ophthalmology. 2005 Nov 25;5:27.

Jager, R., Timothy, N., Coney, J., Katalinic, P., Cavicchi, R., Cavallerano, J., Aiello, L. Congenital Retinal Macrovessel.
Retina. 2005 Jun;25(4):538-540.

Jager R., Aiello, L., Patel S., Cunningham, E. Risks of Intravitreous Injection: A Comprehensive Review.
Retina. 2004 Oct;24(5):676-98.

Shahinian, L., Jain, S., Jager, R., et al. Dilute Topical Proparacaine for Pain Relief after Photorefractive Keratectomy.
Ophthalmology 1997; 104: 1327-1332.

Heymann, J., Jager, R., Subramaniam, S. Expression of Bacteriorhodopsin in Sf9 and COS-1 Cells.
Journal of Biomembranes and Bioenergetics 1997; 29: 55-59.

Jager, R., Chen, F. Musculoskeletal Photodiagnosis: Hereditary Multiple Exostoses.
Journal of Musculoskeletal Medicine 1998; 15(6): 63-64.

Presentations

Veeral S. Sheth, MD, MBA, FASRS, FACS, University Retina & Macular Associates

• Barakat MR, Aziz A, Khan H, Lauer E, Mohan N, Viruni N, Mishra K, Nielsen JS, Abbey AM, Almeida D, Corradetti G, Haug SJ, Sheth VS, Sadda SR, Khanani AM. Retinal fluid quantification using a novel AI-based algorithm in patients treated with faricimab in the TRUCKEE study: First time results. ASRS presentation, 2023.
• Eichenbaum DA, Holekamp NM, Khanani AM, Pieramici DJ, Hershberger VS, Sheth VS, Ma L, Brunstein F, Indjeian V, Hsu J, Dere R, Maia M, Gao S, Willis J, Wiley H, Chen H. Efficacy and safety of anti-high temperature requirement A1 (aHtrA1) Fab in geographic atrophy (GA) secondary to AMD: Gallego phase 2 randomized trial. ASRS presentation, 2023.
• Nezgoda J, Aziz A, Khan H, Khan Hu, Abbey AM, Almeida D, Avery RL, Banda H, Barakat MR, Bhandari R, Chang EY, Corradetti G, Danzig CJ, Graff JM, Haug SJ, Javaheri M, Liu EM, London NJ, Nielson J, Sadda SR, Sheth VS, Singer MA, Wolfe JD, Wong RW, Khanani AM. Real world efficacy, durability, and safety of faricimab in diabetic macular edema: the TAHOE study. ASRS presentation, 2023.
• Sheth V. Three-year outcomes from the PALADIN phase IV study: a comparison of anatomical metrics pre- and post-0.19mg fluocinolone acetonide treatment and their relationship to efficacy and treatment burden outcomes. Retina Society presentation, 2022.
• Sheth V, Khan H, Aziz AA, Abbey AM, Almedia DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Danzig CJ, Haug SJ, London NJS, Singer MA, Wolfe JD, Khanani AM. Real world efficacy, durability, and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study. Euretina paper presentation, 2022.
• Sheth V. Three year outcomes from the PALADIN phase IV study: a comparison of anatomical metrics pre- and post-0.19mg fluocinolone acetonide treatment and their relationship to efficacy and treatment burden outcomes. Euretina paper presentation, 2022.
• Barakat M, Singh RP, Ip M, Higgins PM, Sheth V, Eichenbaum D, Wykoff C, Kim YS, He F, Cho G, Wang Y, Emanuelli A. Brolucizumab for the treatment of diabetic macular edema: 52-week results from the KINGFISHER study. Euretina paper presentation, 2022.
• Sheth V, Blotner S, Heinrich D, Gune S, Chakravarthy U. Central subfield thickness fluctuations and their impact on vision outcomes over 96 weeks in the Archway trial of the PDS. ASRS paper presentation, 2022.
• Bhagat D, Bhatt H, Chittaluru N, George M, Jager R, Patel P, Sheth V. Evaluating patient perspective regarding telehealth for retinal disease during the COVID-19 pandemic. ASRS poster presentation, 2022.
• Holekamp N, Adam MK, Chi G, Garmo V, Gentile B, Lambert J, Lewis H, Mirt M, Pahwa A, Sheth V. Patient and caregiver experience with anti-VEGF intravitreal injections to treat neovascular age-related macular degeneration and diabetic macular edema in the US. ASRS poster presentation, 2022.
• Khan H, Eichenbaum D, Ewing T, Graff T, Khan M, Khanani A, Masud M, Sheth V, Sulahria H. Real world efficacy and safety of the ranibizumab port-delivery system in neovascular AMD: the SUMMIT study. ASRS poster presentation, 2022.
• Sheth V, Peto T, Lambert J, Lewis H, Barbier V, Gentile B, Mirt M, Chi G. Patient experience with anti-VEGF intravitreal injections in neovascular age-related macular degeneration and diabetic macular edema: a multinational observational study. ARVO poster presentation, 2022.
• Modi Y, Csaky K, Sheth V, Willis J, Haskova Z, Westenskow P. Angiopoietin-2 (Ang-2) signaling and vascular stability with faricimab in diabetic macular edema (DME). ARVO poster presentation, 2022.
• Chittaluru N, Bhagat D, Patel P, Sheth V. Patient perspective of telehealth for retinal disease during the COVID-19 pandemic. ARVO poster presentation, 2022.
• Sheth V, Khanani A, Chuidian M, Dinh P, Zamiri P. Intravitreal sunitinib malate depot (GB-102): durability and safety in wet age-related macular degeneration (ALTISSIMO, phase 2B). AAO late-breaker presentation, 2021.
• Danzig C, Khanani AM, Eichenbaum D, Wykoff CC, Hsu J, Lally DR, Sheth V, Heier JS, Patel SS, Nielsen J. Avacincaptad pegol demonstrates continued reduction in GA growth: GATHER1 18-month results. AAO poster, 2021.
• Baumal C, Loewenstein A, Sheth VS, Csaky K, Edmonds R, Chang M, Willis JR, Haskova Z, Westenskow PD. Exploring Ang-2 signaling in vascular stability in patients with DME receiving faricimab in phase 2 and phase 3 trials. Retina Society paper presentation, 2021.
• Loewenstein A, Sheth VS, Csaky K, Edmonds R, Chang M, Willis JR, Haskova Z, Westenskow PD. Exploring Ang-2 signaling in vascular stability in patients with DME receiving faricimab in phase 2 and phase 3 trials. Euretina Prize Paper Presentation, 2021.
• Sheth VS, Loewenstein A, Csaky K, Edmonds R, Chang M, Willis JR, Haskova Z, Westenskow PD. Exploring Ang-2 signaling in vascular stability in patients with DME receiving faricimab in phase 2 and phase 3 trials. AAO poster, 2021. Awarded 2021 Best Poster Award.
• Sheth VS, Menezes A, Malhotra V. Key pearls of conjunctival and Tenon’s capsule handling during the implant insertion procedure for the port delivery system with ranimizumab (PDS). ASRS paper presentation, 2021.
• Sheth VS. Avacincaptad pegol, a novel C5 inhibitor, demonstrates a continued reduction in the mean rate of geographic atrophy growth: 18-month results from the GATHER1 clinical trial. ARVO paper presentation, 2021.
• Sheth VS, Blotner S, Malhotra M, D’Rozario MR, Gune S. Fluctuations in central foveal thickness and vision outcomes with anti-VEGF therapy for neovascular age-related macular degeneration. ASRS paper presentation, 2020.
• Bhagat D, Kirby B, Bhatt HK, Jager RD, Sheth VS. Evaluating patient preferences when receiving intravitreal injections for retinal disease: A conjoint analysis. ASRS poster presentation, 2019.
• Sheth V. Subthrehold micropulse laser for chronic central serous chorioretinopathy. 19th Annual Club Vit Meeting. Miami, USA. July 2, 2016.
• Miller RC, Yashraj C, Jager R, Bhatt H, Sheth V. Visual and anatomic outcomes of combined focal navigated laser photocoagulation and intravitreal anti-vascular endothelial growth factor for diabetic macular edema. ARVO poster presentation, 2015.
• Feinstein E, Miller RC, Yashraj C, Jager R, Bhatt H, Sheth V. Visual and anatomic outcomes of focal navigated laser photocoagulation for diabetic macular edema at 12 months. ARVO poster presentation, 2015.
• Sheth V. Subthreshold 577nm micropulse laser for diabetic macular edema. 23rd Annual Conference of the Vitreo Retinal Society of India. Agra, India. December 6, 2014.
• Sheth V. Symptomatic vitreomacular adhesion: current options. 23rd Annual Conference of the Vitreo Retinal Society of India. Agra, India. December 5, 2014.
• Sheth V. The perceptions of policy: the ACA and its impact on clinical practices. AMSA Training Ground Conference. Chicago, USA. November 22, 2014.
• Sheth V. Advancements in retinal diagnostics and therapeutics. Joliet Optometric Society. Lemont, USA. January 26, 2014.
• Sheth V. New treatments and innovations in diabetic and age-related retinal diseases. Adventist Bolingbrook Hospital Grand Rounds. Bolingbrook, IL. October 1, 2013.
• Sheth V. Retina review. Cook County Ophthalmology Comprehensive Overview. Chicago, USA. March 3, 2013.
• Sheth V. Advancements in retinal diagnostics and therapeutics. Joliet Optometric Society. Lemont, USA. January 27, 2013.
• Agrawal KK, Jager RD, Bhatt HK, Sheth VS. Combination therapy of intravitreal bevacizumab and focal NAVILAS laser in the treatment of macular edema due to branch retinal vein occlusion. American Society of Retinal Specialist poster presentation, 2012.
• Sheth V. DRCR.net treatment of DME with triamcinolone vs ranibizumab vs laser and future trials. 6th Asia-Pacific Vitreo Retina Society Congress held in conjunction with the 20th Annual Conference of the Vitreo Retinal Society of India. Hyderabad, India. December 1, 2011.
• Sheth V. Inflammatory retinal edema. 6th Asia-Pacific Vitreo Retina Society Congress held in conjunction with the 20th Annual Conference of the Vitreo Retinal Society of India. Hyderabad, India. December 2, 2011.
• Sheth V. Retina review. Cook County Ophthalmology Comprehensive Overview. Chicago, USA. March 20, 2010.
• Colina-Luquez J, Mojica G, Sheth V, Hariprasad SM. Incidence of endogenous fungal endophthalmitis in patients with positive blood cultures for systemic fungemia. ARVO poster presentation, 2010.
• Chen JJ, Eulo V, Huang Y, Rehman J, Hariprasad SM, Jager RD, Sheth V, Chiranand P, Mojica G, Nicolae DL, Lussier YA, Grassi MA. Study of genetic expression in diabetic retinopathy reveals unique molecular fingerprint. ARVO poster presentation, 2010.
• Gabrielian A, Sheth V, Hariprasad SM. Surgical outcomes of epiretinal membrane removal with and without internal limiting membrane peel in patients with tractional retinal detachment. ARVO poster presentation, 2009.
• Sheth V, Blair M, De la Cruz J. Macular optical coherence tomography findings in Boston type 1 keratoprosthesis patients at the Illinois Eye and Ear Infirmary. ARVO poster presentation, 2008.
• Slover C, Sheth V, Danziger L, Tu E, Fiscella R. Evaluation of topical linezolid, daptomycin, and tigecycline compared to vancomycin in a rabbit model of Streptococcus pneumoniae corneal ulceration. ARVO poster presentation, 2007.
• Sheth V, Clement C, Tiwari V, Scanlan PM, Valyi-Nagy T, Shukla D. Herpes simplex virus receptor Nectin-1 expression in the murine eye. ARVO poster presentation, 2004.

Harit K. Bhatt, M.D., M.B.A, F.A.C.S., FASRS, University Retina & Macular Associates

Meena S. George, M.D., Ph.D., FASRS, University Retina & Macular Associates

Bhagat D, Bhatt H, Chittaluru N, George M, Jager R, Patel P, Sheth V. Evaluating patient perspective regarding telehealth for retinal disease during the COVID-19 pandemic. ASRS poster presentation, 2022.  

Rama D. Jager, M.D., M.B.A., F.A.C.S., University Retina & Macular Associates

Bhavsar A, Williams D, Jager RD. Intravitreal Injections: Sound Technique and Risk Reduction. Instructional Course. 2012 American Society of Retinal Specialists Annual Meeting.

Agarwal K, Bhatt HK, Sheth VS, Jager RD. Combination Therapy of Intravitreal Bevacizumab and Focal NAVILAS Laser in the Treatment of Macular Edema due to Branch Retinal Vein Occlusion. Poster Presentation. 2012 American Society of Retinal Specialists Annual Meeting.

Afshar A, Amara M, Grandhe S, Jager R. Focal Laser Treatment for Diabetic Macular Edema with the NAVILAS Navigated Laser Photocoagulation System. American Society of Retinal Specialists. Poster Presentation. 2011 Annual Meeting.

Agarwal K, Patel R, Jager R. Macular Schisis Following Indocyanine Green-Assisted Internal Limiting Membrane Peel for Epiretinal Membrane Surgery. ARVO 2011

Afshar A, Patel R, Jager R. Outcomes of Focal Laser Treatment for Diabetic Macular Edema with the NAVILAS Navigated Laser Photocoagulation System. ARVO 2011

Jager R, Miller J, Mieler W, Bressler N, Lim J, Cousins S. Age-related Macular Degeneration – Program Chair of the Symposium at the American Academy of Ophthalmology Annual Meeting in Chicago, 2010.

J. J. Chen, V. Eulo, Y. Huang, J. Rehman, S. M. Hariprasad, R. D. Jager, V. Sheth, D. L. Nicolae, Y. A. Lussier, and M. A. Grassi Study of Genetic Expression in Diabetic Retinopathy Reveals Unique Molecular Fingerprint ARVO Meeting ARVO 2010

R. M. Grutsch, D. F. Kiernan, R. D. Jager, and M. A. Saidel Demographic and Clinical Features of Anterior Uveitis in Female Patients at a University Ophthalmology Center in Chicago ARVO 2009.

D. F. Kiernan, S. M. Hariprasad, R. Singh, R. D. Jager, and W. F. Mieler The Association of Daily Anticoagulant Use and Intraocular Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration ARVO Meeting Abstracts April 11, 2009 50:3499

G. J. Burrell, S. M. Hariprasad, W. F. Mieler, and R. D. Jager Improvement in Visual Quality of Life After Traditional and Microincisional Vitrectomy Surgery ARVO 2008

A. J. Dave, A. Gabrielian, R. Lin, T. Lin, S. Hariprasad, R. Jager, J. Rago, J. Ernest, and V. Arun A Comparison of Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) in The Diagnosis and Assessment of Diabetic Macular Edema ARVO 2008

B. K. Williams, Jr., D. F. Kiernan, R. D. Jager, R. Lin, and W. F. Mieler The Effect of Internal Limiting Membrane Peel During Epiretinal Membrane Removal on Visual Acuity and Recurrence Rate in Diabetic and Non-Diabetic Eyes ARVO 2008

K. Grant-Acquah, D. F. Kiernan, R. D. Jager, and W. F. Mieler Intraoperative Use of Kenalog for Epiretinal Membrane Removal Is Associated With Improved Visual Outcomes and Decreased Membrane Recurrence ARVO 2008

R. Singh, A. P. Singh, A. Flaum, K. Grant-Acquah, D. Kiernan, N. James, W. Mieler, and R. D. Jager Comparative Transatlantic Survey of Patient Knowledge and Awareness of Hypertension and Its Effects on Eye Disease ARVO 2008

Johnson, V., Hariprasad, S., Grassi, M., Green, J., Jager, R., Mieler, W. The Impact of Diabetic Retinopathy on Vision-Related Quality of Life Ophthalmology. Poster presentation at the 2007 ARVO Annual Meeting.

Albin, S., Benevento, J., Chang, J., Jager, R. Diabetic Retinopathy Knowledge in University Clinic Patients. Poster presentation at the 2007 ARVO Annual Meeting.

Mazzulla, D., Hariprasad, S., Mojica, G., Radhakrishnan, C., Jager, R., Mieler, W. Short-Term Intraocular Trends Following Intravitreal Injection of Bevacizumab (Avastin). Poster presentation at the 2007 ARVO Annual Meeting.

Belsare, G., Hariprasad, S., Jager, R., Mazzulla, D., Mieler, W.. Effects on Visual Acuity and OCT Following Older Generation AMD Treatment With Subsequent Lucentis or Avastin Intravitreal Injections. Poster presentation at the 2007 ARVO Annual Meeting.

Miller, L., Mojica, G., Hariprasad, S., Mieler, W., Grassi, M., Green, J., Jager, R. Vision-Related Quality of Life in Patients With Diabetic Macular Edema. Poster presentation at the 2007 ARVO Annual Meeting.

Jager R., Aiello, L.P., Patel S.C., Cunningham, E.T. Complications of Intravitreal Injections: An evidence-based review. Paper presentation at the 2004 American Society of Retinal Specialists Annual Meeting.

Jager, R., Timothy, N., Coney, J., Keenan, H., Arrigg, P., Aiello, L.P. Endophthalmitis as a Complication of Intravitreal Injection: A Systematic Review. Poster presentation at the 2004 ARVO Annual Meeting.

Coney, J., Brathwaite, C., Jager, R., Doria, A., Timothy, N., Aiello, L.P. Clinical Characteristics of Complications in Patients with 50 or More Years of Type 1 Diabetes Mellitus. Poster presentation at the 2004 ARVO Annual Meeting.

Jager, R., Rubin, M., Albanis, C., et al. Rates of Posterior Capsular Rupture and Vitreous Loss During Phacoemulsification in the Presence or Absence of Diabetes and Hypertension. Poster presentation at the 2002 ARVO Annual Meeting.

Rubin, M., Goins, K., Jager, R., Albanis, C., Dwyer, M., Ernest, J. Comparison of Phacoemulsification Complication Rates in a University Setting Using Venturi and Peristaltic Machines. Poster presentation at the ARVO 2002 Annual Meeting.

Jager, R., Jain, S., et al. The Effect of Topical Dilute Proparacaine on Relief of Postoperative PRK Pain. Poster presentation at the 1996 ARVO Annual Meeting.

Abstracts

Harit K. Bhatt, M.D., M.B.A, F.A.C.S., FASRS, University Retina & Macular Associates

VBS 2015
Headache after macular hole repair. ARVO 2015:

Visual and Anatomic Outcomes of Combined Focal Navigated Laser Photocoagulation and Intravitreal Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema
Visual and Anatomic Outcomes of Focal Navigated Laser Photocoagulation for Diabetic Macular Edema at 12 months

ASRS 2015:

Efficacy of Intravitreal Bevacizumab in Eyes with Myopic Choroidal Neovascularization Without Intraretinal or Subretinal Fluid on Spectral-domain OC

Ocular Emergencies. Advocate Christ Hospital Grand Rounds. 2010-2011. Office-Based Ophthalmology. Advocate Christ Hospital Grand Rounds. 2010-2011.

Aggrawal K, Jager R, Bhatt H, Sheth V. Combination therapy of intravitreal Bevacizumab and focal NAVILAS laser in the treatment of macular edema due to branch retinal vein occlusion. ASRS 2012.

Bhatt HK, Lyon A. Oxygen Treatment of Macula-off Retinal Detachments. Northwestern University Alumni Day. 2010.

Bhatt HK, Lyon A. Pediatric Retinal Detachments. Northwestern University Pediatric Eye Conference. 2010.

Reck P, Bhatt HK, Shapiro MJ. Outcomes of Pediatric Open Globes. ARVO 2008.
Reck P, Bhatt HK, Shapiro MJ. Pediatric Open Globes. Annual Pediatric Retina Conference University of Illinois at Chicago 2007
Chicago, IL

Blair NP, Bhatt HK, Buerk BM, Sharma MC. Traumatic Open Globe Injuries: Characteristics of Older Patients with Open Globes.
Presented at Universtiy of Illinois Alumni Day.

Bhatt HK. Pneumocephalus after Macular Hole Repair. Rabb Retina Study Club 2006-2011 Chicago, IL

Blair NP, Sharma MC, Bhatt HK, Buerk BM. Traumatic Open Globe Injuries: Characteristics of Older versus Younger Patients. ARVO 2004

Sharma MC, Bhatt HK, Buerk MB, Blair NP, McDonald TB, Fine BA, Gunnerson HB. Drug Screening in Patients with Open Globe Injury. ARVO 2004.

Other

Veeral S. Sheth, MD, MBA, FASRS, FACS, University Retina & Macular Associates

• Radcliffe N, Sheth VS. IOP changes in patients with uveitis. Retinal Physician. 2021 Sep: 28-30.
• Sheth VS. Intraocular long-term anti-inflammatory treatment for noninfectious uveitis. Retinal Physician. 2020 Sep: 44-46.
• Sheth, VS. Vision, drugs, and money. Ophthalmology Management. 2017 Aug:18-21.
• Hariprasad SM, Boyer DS, Fine HF, Khurana RN, Ober MD, Sheth VS, Singer MA. Evolving strategies in the use of corticosteroids for the treatment of DME. Retinal Physician. 2015 Apr: 6-19.
• Farooq AV, Miller RC, Sheth VS. Case of the month. The New Physician. 2015 Jan-Feb: 34-35.
• Miller RC, Sheth VS. Removal of intraocular foreign body: new technique. ASRS.org. 2014 Dec.
• Sheth VS, Hariprasad SM. DME drugs multiply. Ophthalmology Management. 2014 Nov; 18:16-18.
• Collins ME, Sheth V, Raichand S, Saidel MA, Hariprasad SM. Microincisional suttureless vitrectomy for dislocated IOL. 2009 Retina Today. Nov/Dec: 32-35.
• Sheth V, Lin TK, Kiernan DF, Jager RD. Cilary neurotrophic factor in the treatment of advance nonexudative age-related macular degeneration. Retrieved September 29, 2009, from AMD Update. Web site: http://www.lwwvisioncare.com/emails/amdupdate/index.asp?issue=33.

Harit K. Bhatt, M.D., M.B.A, F.A.C.S., FASRS, University Retina & Macular Associates

Research

Sub-Investigator (2022-Present)
GR43828: A Phase I, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema. Sponsor: Genentech

Rama D. Jager, M.D., M.B.A., F.A.C.S., University Retina & Macular Associates

Books

Sheth, V., Marcet, M., Bhatt, H., Chiranand, P., Lamkin, J., Jager, R. The Massachusetts Eye & Ear Infirmary Review Manual for Ophthalmology, 4th Edition. Lippincott, Williams & Wilkins, 2011 (ISBN: 1451111363)

Jager, R., Lamkin, J. The Massachusetts Eye & Ear Infirmary Review Manual for Ophthalmology, 3rd Edition. Lippincott, Williams & Wilkins, 2006 (ISBN: 0781758130)

Alfaro, V., Liggett, P., Mieler, W., Quiroz-Mercado, H., Jager, R., Tano, Y. Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006 (ISBN: 0781738997)

Jager, R., Ortiz, R. In the Company of Giants: Candid Conversations with the Visionaries of the Digital World. McGraw-Hill, 1997 (ISBN: 0-07-03294-6)

Study Experience (For Which Was A Principal Investigator or Sub Investigator)

Genentech/DME Protocol GR40398 (RHINE) 
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema 

Genentech/wAMD Protocol GR40844 (LUCERNE)
A Phase II, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration 

Genentech/GA Protocol GR40973 (GAllego)
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Evidence of Activity of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration 

Ionis/GA Protocol ISIS 696844-CS5
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) 

Gyroscope/GA Protocol GTSCOPE
A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration 

Genentech/ DME Protocol BP41321 (Canberra)
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients with Diabetes Mellitus Type 1 or Type 2 with Treatment-Naive Diabetic Retinopathy 

Regeneron/ wAMD Protocol VGFTe-HD-AMD-1905 (Candela)
A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration 

Genentech/ wAMD Protocol GR40548 (Archway)
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration 

Genentech/ DME Protocol GR40550 (PAGODA)
A Phase III, Multicenter, Randomized, Visual Assessor Masked, Active Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema 

Genentech/ DR Protocol GR41675 (Pavillion)
A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy 

Chengdu Kanghong/ wAMD Protocol KHB-1801 (PANDA)
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration  

GrayBug Vision/ wAMD Protocol GBV102-002 (Altissimo)
A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration   

Outlook/ wAMD Protocol ONS-5010-002 
A Clinical Effectiveness, Multicenter, Randomized, Double-Masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) 

Novartis/ DME Protocol CRTH258B2305 (Kingfisher)
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Every 4 Weeks Versus Aflibercept Every 4 Weeks in Adult Patients with Visual Impairments due to Diabetic Macular Edema 

Clearside/ RVO Protocol CLS-1003-302 (Topaz)
A Randomized, Masked, controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination with an Intravitreal Anti-VEGF in Subjects with Retinal Vein Occlusion 

SalutarisMD/ wAMD Protocol SMD-201601
A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age-Related Macular Degeneration

DRCR/ CI-DME Protocol AC
A Randomized Trial of Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema.

Aerpio/ NPDR Protocol AKB-9778-CI-5001
Phase 2 Double-Masked, Placebo-Controlled Study to access the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy

Regeneron/ NPDR Protocol VGFTe-OD-1411
Phase 3, Double-Masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe non-proliferative diabetic retinopathy 

Allergan/ wAMD Protocol 150998-005/150998-006 (Cedar/Sequoia)
Safety and Efficacy of Aflibercept Pegol (AGN-150998) in patients with Neovascular Age-related Macular Degeneration 

Genentech/ GA Protocol GX29176 (Chroma)
Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to Age-related Macular Degeneration 

Tyrogenex/ wAMD Protocol X82-OPH-201
A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority study of X-82 plus prn IVT Anti-VEGF compared to prn IVT Anti-VEGF monotherapy in Neovascular AMD 

Alimera Science/ DME Protocol M-01-15-004 (Iluvien)
Phase 4 safety study of IOP signals in patients treated with Iluvien (Fluocinolone Acetonide Intravitreal Implant) 0.19mg 

Genentech/ DME Protocol BP30099 (Boulevard)
A Multi-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Diabetic Macular Edema.

Regeneron/ wAMD Protocol R910-3-AMD-1517 
A Randomized, Double-Masked, Active-Controlled Phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with Neovascular Age-related Macular Degeneration 

Regeneron/ wAMD Protocol R2176-3-AMD-1417
Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with Neovascular Age-related Macular Degeneration

Opthotech/ wAMD Protocol OPH1006
Effect of Anti-VEGF agents administered on a quarterly maintenance regimen in subjects with Neovascular AMD receiving Anti-PDGF Therapy: An 18 month Phase 2a Open Label, Randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)

Opthotech/ wAMD Protocol OPH1005
OPH1005B- Sub-Retinal Fibrosis in Neovascular AMD:  24 month Phase 2A Open Label safety study of Fovista (Anti-Pegylated Aptamer) regimen administered in combination with Anti-VEGF Therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy 

Opthotech/ wAMD Protocol OPH1004B
Phase 3 Randomized, Double-Masked, Controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (Anti-PDGF-B Pegylated Aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea Monotherapy in subjects with subfoveal Neovascular Age-related Macular Degeneration 

DRCE/ CI-DME Protocol V
Treatment for Center-Involved Diabetic Macular Edema in eyes with very good visual acuity 

Alcon/ wAMD Protocol LHA510-2201 (Alcon)
A Randomized, Double-Masked, Vehicle-Controlled, Proof-of-Concept study for topically delivered LHA510 as a maintenance therapy. 

Thrombogenics/ Vitreomacular Adhesion/Vitreomacular Traction Protocol ORBIT
A Multicenter, prospective observational study assessing the clinical outcomes and safety of patients receiving JETREA® in a real-world setting for the treatment of symptomatic VMA/VMT following standard of care from US retina clinics.

ALCON / ARRT Protocol C-02-60
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients (Enrolled in Study “A” or Study “B”) at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age-Related Macular Degeneration 

ALIMERA / FAME
A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 micrograms/day and ASI-001B 0.2 micrograms/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema 

ALIMERA / FAME-Extension
An open label, multi-center extension study of the safety and utility of the new inserter of ILUVIEN (Fluocinolone Acetonide Intrvitreal Insert) 0.19mg and the safety of ILUVIEN in subjects with diabetic macular edema.

ALLERGAN / RVO
A Six-Month, Phase III, Multicenter, Masked, Randomized, Sham-Controlled Trial (With Six-Month Open Label Extension) to Assess the Safety and Efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.

ALLERGAN / DME Protocol AGN206207-011-01
A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema. 

FOVEA PHARMACEUTICALS / FOV2304   (Fovea)
A 6 month ,phase II, double-masked, multicenter, randomized, placebo-controlled, parallel group study to assess the safety and efficacy of topical adminitration of two concentrations of FOV2304 (1% and 2%) twice daily for the treatment of center-involving clinically significant Macular Edema associated with Diabetic Retinopathy. 

GENENTECH / FVF4579g (HARBOR)                                           
A Phase III, Double-Masked, Multicenter, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and  2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neoascular Age-Related Macular Degeneration   

GENENTECH / FVF4967g (SHORE) 
A multicenter randomized study evaluating dosing regimens for treatment with intravitreal ranibizamab injections in subject with macular edema following retinal vien occlusion.

NEI|DRCR / SCORE
A Randomized Trial to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema Associated with Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion 

REGENERON / Protocol VGFT-OD-0508
A Randomized Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration Clinical Evaluation of Anti-Angiogenesis in the Retina Intravitreal Trial AMD Phase 2 (CLEAR-IT AMD-2)  

REGENERON / VEGF-TRAP 0502
An Exploratory Study of the Safety, Tolerability and Biological Effect of Intravitreal Administration of  VEGF Trap in Patients with Neovascular Age- Related Macular Degeneration (VGFT-OD-0502)